FindTrial
Sign In

effect of gasteroesophageal reflux treatment in cystic fibrosis

evaluation of the effect of gasteroesophageal reflux treatment on improving pulmonary function in patients with cystic fibrosis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230312057688N1
Enrollment
20
Registered
2023-05-01
Start date
2023-04-19
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis. Cystic fibrosis

Interventions

Intervention group:cystic fibrosis patients with gasteroesophageal reflux are treated with proton pomp inhibitors and spirometery is compared before and after the intervention.

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to No maximum

Inclusion criteria

Inclusion criteria: Cystic fibrosis patients over 6 years old Not having advanced respiratory disease

Exclusion criteria

Exclusion criteria: patients treated with proton pump inhibitors patients with severe pulmonary disease non adherence to pulmonary treatments

Design outcomes

Primary

MeasureTime frame
Forced vital capacity. Timepoint: At the begining of the study and 2 months after the intervention. Method of measurement: spirometery.;Forced effective volume 1 second. Timepoint: At the begining of the study and 2 months after the intervention. Method of measurement: spirometery.;Forced Effective Volume 25-75. Timepoint: At the begining of the study and 2 months after the intervention. Method of measurement: spirometery.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham pourazar

Ahvaz University of Medical Sciences

pourazar-e@ajums.ac.ir0098 61

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026